Lipocine Inc (LPCN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.53+6.25%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · LPCN
Next print, the company's guidance track record, and the earnings events we've seen in the last few years.
Likelihood the company beats analyst consensus on its next print. Read from its own beat history plus how sector peers have been reporting. Not a price-direction call: a serial beater often has the beat already priced in.
Prints it beat consensus, recent quarters.
Indicative, not a guarantee. Base rate ~71%.
Industry peers that beat since this name last reported.
Management's most recent EPS guidance action.
expected = 0.35*own_median(9.5) + peer(0.2*0.0) + term(0.0) → 3.32% (capped ±15.0)
Calibrated likelihood the company misses analyst consensus on its next print, read from its own miss history plus its industry base rate. A fundamental tilt, not a price call — and a quiet watch-flag, not an alarm.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Calibrated. Base rate ~24%.
Consecutive quarters it missed, most recent run.
How often this industry misses, baseline.
Industry peers that missed in the recent window.
today
Average absolute move on past earnings days.
Annualized: recent baseline volatility.
Of the last 0 guided quarters.
Actual vs. guided EPS, signed.
Excess return vs. sector ETF, day after print.
Earnings prints and pre-announcements detected in the SEC filing stream.
Results of Operations and Financial Condition. On November 5, 2026, the Company issued a press release announcing financial and operational results for the quarter ended September 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…
Quarterly EPS and revenue actuals vs. consensus across the last eight quarters (including beat/miss size and the forward consensus heading into the next print) are on the way.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Results of Operations and Financial Condition. On August 4, 2026, the Company issued a press release announcing financial and operational results for the quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Results of Operations and Financial Condition. On May 7, 2026, the Company issued a press release announcing financial and operational results for the quarter ended March 31, 2026. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…
Results of Operations and Financial Condition. On March 10, 2026, the Company issued a press release announcing financial and operational results for the year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Excha…
Results of Operations and Financial Condition. As of January 31, 2026, Lipocine Inc. (the “Company”) had approximately $19 million of cash and cash equivalents. The foregoing estimate is preliminary and unaudited and reflects the Company’s preliminary estimates with respect to its cash at January 31, 2026, based on currently available information and is subject to completion of financial closing procedures. This estimate should not be viewed as a substitute for the Company’s annual financial…
Results of Operations and Financial Condition. On November 6, 2025, the Company issued a press release announcing financial and operational results for the quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the…
Results of Operations and Financial Condition. On August 5, 2025, the Company issued a press release announcing financial and operational results for the quarter ended June 30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this report and incorporated by reference herein. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchan…
Results of Operations and Financial Condition On March 7, 2024, the Company issued a press release announcing financial and operational results for the year ended December 31, 2023. The press release is filed as Exhibit 99.1 and is incorporated herein by reference.
Results of Operations and Financial Condition. On January 25, 2021, Lipocine Inc., (the “Company”) commenced an underwritten public offering of its common stock (the "Offering") pursuant to its effective shelf registration statement (File No. 333-250072) declared effective by the Securities and Exchange Commission (the “SEC”) on November 23, 2020. On January 25, 2021, the Company issued a press release announcing the commencement of the Offering. The text of the press release is included as E…